<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a series of 102 patients with angiographically proven cerebral sinus <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e>) significant differences with arterial cerebrovascular disease were noted with respect to disease <z:hpo ids='HP_0003674'>onset</z:hpo>, reversibility of symptoms, occurrence of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e> <z:hpo ids='HP_0001250'>seizures</z:hpo> and <z:hpo ids='HP_0002315'>headache</z:hpo>, cerebral blood flow under resting and stimulated conditions, occurrence of <z:mp ids='MP_0001915'>intracranial bleedings</z:mp>, and response to <z:chebi fb="5" ids="28304">heparin</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>From these findings pathophysiological differences are hypothesized: Whereas arterial <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> usually is a monophasic abrupt thrombotic process and there is only a small penumbra, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> is a continuing process of disequilibrium between prothrombotic and thrombolytic mechanisms; large areas of the brain are only functionally or metabolically disturbed but not irreversibly damaged </plain></SENT>
<SENT sid="2" pm="."><plain><z:mp ids='MP_0001915'>Intracranial bleeding</z:mp> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> is a consequence of increased venous and capillary pressure and thus occurs more frequently than in arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombotic disease</z:e> in which capillary pressure is reduced by the <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:mp ids='MP_0001914'>bleeding</z:mp> occurs during reperfusion of tissue damaged by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> treatment in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> is effective since it shifts the equilibrium away from the prothrombotic side and is able to save large areas of brain tissue that are only reversibly damaged </plain></SENT>
<SENT sid="4" pm="."><plain>It improves venous outflow and thus decreases the risk of <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo>, in contrast with the arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombotic disease</z:e> where <z:chebi fb="5" ids="28304">heparin</z:chebi> increases the risk or at least the severity of <z:mp ids='MP_0001915'>intracranial bleedings</z:mp> </plain></SENT>
</text></document>